Therapeutic Response

Wild type HRAS and Wild type KRAS status confers therapeutic sensitivity to Fluorouracil in combination with Oxaliplatin and Panitumumab in patients with Colorectal Adenocarcinoma.

Statements

Source and description

Vectibix (panitumumab) [package insert]. FDA. The U.S. Food and Drug Administration granted approval to panitumumab in combination with FOLFOX for the first-line treatment of patients with wild-type RAS (defined as wild-type in both KRAS and NRAS, as determined by an FDA-approved test for this use) metastatic colorectal cancer (mCRC). The product label specifies a limitation of use that panitumumab is not indicated for the treatment of patients with RAS-mutant mCRC or for whom RAS mutation status is unknown.